Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01815619
Other study ID # 409832
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2013
Est. completion date August 25, 2020

Study information

Verified date August 2023
Source AdventHealth
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test two different methods for processing biopsy specimens taken from the bile duct. Patient;s who are asked to participate int his study have a stricture in the bile duct that needs a single operator cholangioscopy-guided biopsies during endoscopic retrograde cholangiopancreatography (ERCP) so that a diagnosis can be made. Standard of care includes performing single operator cholangioscopy-guided biopsies in the bile duct and sending the tissue to the lab for testing to make a diagnosis. Using this method the investigators can establish a diagnosis only about 50% of the time. The investigators believe that if a cytopathologist is available in the endoscopy suite during the procedure to evaluate the biopsy specimens onsite, the investigators can improve the diagnostic accuracy. The purpose of this study is to compare two methods for processing biopsies obtained from the bile duct (Onsite vs. Offsite).


Description:

The diagnostic accuracy rate of single operator cholangioscopy-guided biopsy is only 50%. This translates to the need for performing repeat procedures to establish a diagnosis and therefore delays patient treatment. The biopsy specimen obtained at cholangioscopy are usually processed offsite in the pathology lab. We believe that if a pathologist can assess the tissue sample during the procedure itself (onsite) and provide feedback, the diagnostic accuracy rate will improve. This translates to better (faster) diagnosis and early treatment. Therefore, we will be comparing onsite versus offsite evaluation of bile duct biopsy specimens to determine which method yields a better diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date August 25, 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Age > 18 years - Suspected biliary stricture Exclusion Criteria: - Age < 18 years - Pregnancy - Altered surgical anatomy - Irreversible elevation in INR > 1.5 or low platelet count < 50,000

Study Design


Related Conditions & MeSH terms


Intervention

Other:
on-site specimen evaluation
The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
off-site specimen evaluation
The specimen will be evaluated off-site by a cytopathologist

Locations

Country Name City State
United States AdventHealth Orlando Orlando Florida

Sponsors (2)

Lead Sponsor Collaborator
AdventHealth University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of cholangioscopy-directed biopsies of bile duct strictures The primary endpoint of the study is to compare the diagnostic accuracy rates between two different methods used for processing specimens obtained from the bile duct. up to18 months
Secondary Specimen evaluation The secondary endpoint of the study is for specimen evaluation results deemed as malignant; benign; suspicious; atypical, or non-diagnostic. up to18 months
Secondary Operating characteristics The secondary endpoint of the study is to assess the operating characteristics through review of the sensitivity, specificity, negative predictive value and positive predictive value between the on-site group and the off-site group. up to18 months
Secondary Costs difference between the onsite and offsite procedures The secondary endpoint of the study is to review and compare total costs of the onsite group in comparison to the total costs of the off-site group. up to 18 months
Secondary Number of biopsies to achieve diagnosis The secondary endpoint of the study is to compare between on-site and off-site specimen for the number of biopsies to achieve diagnosis up to 18 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04550819 - Intraintestinal Extended Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture N/A
Completed NCT04112030 - Role of DIA in Diagnosing Nature of Indeterminate Biliary Duct Stricture
Recruiting NCT04929821 - UNITY-B A Prospective, Multicentric, Single-arm Study to Evaluate the Safety and Efficacy of the UNITY-B Biodegradable Balloon-Expandable Biliary Stent System in Subjects With Biliary Strictures N/A
Completed NCT02000999 - Diagnosis of Bile Duct Strictures
Completed NCT01227382 - Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods N/A
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Recruiting NCT01818050 - Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaductâ„¢) Phase 4
Completed NCT02442167 - Performance of FISH for the Diagnosis of Malignant Biliary Strictures in Thai Patients
Recruiting NCT03763214 - PTFE Stents for Treatment of Malignant Biliary Strictures N/A
Recruiting NCT03716232 - Kaffes Stent in the Management of Post-surgical Biliary Strictures Phase 3
Recruiting NCT03310554 - Suspended Overlength Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture N/A
Recruiting NCT03788655 - Metal Stents (Moving Cell Stent) for Inoperable Tumors of the Bile Duct Tract
Completed NCT02276157 - Direct Peroral Cholangioscopy by Using an Ultra-slim Upper Endoscope N/A
Recruiting NCT01414400 - Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography). N/A
Completed NCT05556668 - Percutaneous Biodegradable Biliary Stents for the Treatment of Benign Biliary Strictures.
Recruiting NCT05320497 - Transparent Cap-assisted SpyGlass for Biliary Stricture N/A